Table 2.
SVR24 by Prior pegIFN/RBV Response, n/N (%, 95% CI)
| Prior pegIFN/RBV Response | HCV Subtype 1b Cohort | Genotype 2 Cohort | ||||
|---|---|---|---|---|---|---|
| 12 Weeks | 24 Weeks | 12 Weeks | ||||
| OBVa/PTV/r 100/100 (n = 18) | OBVa/PTV/r 150/100 (n = 18) | OBVa/PTV/r 100/100 (n = 19) | OBVa/PTV/r 150/100 (n = 18) | OBVa/PTV/r 100/100 (n = 19) | OBVa/PTV/r 150/100 (n = 18) | |
| Null responders | 13/13 (100, 75.3‐100) | 12/12 (100, 73.5‐100) | 13/13 (100, 75.3‐100) | 13/13 (100, 75.3‐100) | NA | NA |
| Partial responders | 5/5 (100, 47.8‐100) | 4/6 (66.7, 22.3‐95.7) | 6/6 (100, 54.1‐100) | 5/5 (100, 47.8‐100) | 2/2 (100, 15.8‐100) | 1/1 (100, 2.5‐100) |
| Relapsers | NA | NA | NA | NA | 9/17 (52.9, 27.8‐77.0) | 12/17 (70.6, 44.0‐89.7) |
a
Dose: 25 mg.
Abbreviations: NA, not applicable; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir.